20 June 2020: Clinical Research
Detection of Dysplastic Liver Nodules in Patients with Cirrhosis Using the Multi-Arterial CAIPIRINHA-Dixon-TWIST-Volume-Interpolated Breath-Hold Examination (MA-CDT-VIBE) Technique in Dynamic Contrast-Enhanced Magnetic Resonance Imaging
Ling Fei Guo 1ABCDE , Guihua Gao 2BDF , Zhenguo Yuan 1ADG*DOI: 10.12659/MSM.922618
Med Sci Monit 2020; 26:e922618
Table 2 The display of 33 lesions in 21 patients using the full set of imaging methods.
| Patient code | Lesion code | T2WI | DWI | PV | DL | ESAP | The best phase in MA-CDT-VIBE | The best sequence in DCE | The advantage of MA-CDT-VIBE |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 (5/5) | MA-CDT-VIBE | 1 |
| 1* | 1 | 1 | 1 | 1 | 1 | 1 (5/5) | MA-CDT-VIBE | 1 | |
| 2 | 1 | 1 | 1 | 1 | 2 | 1 (5/5) | MA-CDT-VIBE | 1 | |
| 2* | 1 | 1 | 1 | 1 | 1 | 1 (5/5) | MA-CDT-VIBE | 1 | |
| 3 | 1 | 1 | 1 | 1 | 1 | 1 (4/5) | DL | 1 | |
| 3* | 1 | 1 | 1 | 1 | 1 | 1 (4/5) | DL | 1 | |
| 4 | 1 | 2 | 1 | 1 | 1 | 1 (2/5) | MA-CDT-VIBE | 1 | |
| 4* | 1 | 1 | 1 | 1 | 1 | 1 (2/5) | MA-CDT-VIBE | 1 | |
| 2 | 5 | 1 | 1 | 2 | 1 | 2 | 1 (5/5) | DL | 1 |
| 5* | 1 | 1 | 1 | 1 | 2 | 1 (5/5) | DL | 1 | |
| 6 | 2 | 1 | 1 | 1 | 1 | 1 (4/5) | DL | 1 | |
| 6* | 1 | 1 | 1 | 1 | 1 | 1 (4/5) | DL | 1 | |
| 7 | 1 | 1 | 2 | 1 | 2 | 1 (5/5) | DL | 2 | |
| 7* | 1 | 1 | 1 | 1 | 2 | 1 (5/5) | DL | 1 | |
| 3 | 8 | 2 | 1 | 1 | 1 | 1 | 1 (3/5) | MA-CDT-VIBE | 1 |
| 8* | 1 | 1 | 1 | 1 | 1 | 1 (3/5) | MA-CDT-VIBE | 1 | |
| 9 | 1 | 1 | 1 | 1 | 1 | 1 (5/5) | PV | 1 | |
| 9* | 1 | 1 | 1 | 1 | 1 | 1 (5/5) | PV | 1 | |
| 10 | 2 | 2 | 1 | 1 | 1 | 1 (2/5) | DL | 1 | |
| 10* | 1 | 1 | 1 | 1 | 1 | 1 (2/5) | DL | 1 | |
| 4 | 11 | 1 | 1 | 2 | 1 | 2 | 2 (--) | DL | 2 |
| 11* | 1 | 1 | 1 | 1 | 2 | 1 (5/5) | DL | 2 | |
| 12 | 1 | 1 | 1 | 1 | 1 | 1 (3/5) | MA-CDT-VIBE | 1 | |
| 12* | 1 | 1 | 1 | 1 | 1 | 1 (3/5) | PV | 1 | |
| 5 | 13 | 2 | 1 | 1 | 1 | 1 | 1 (4/5) | MA-CDT-VIBE | 1 |
| 13* | 1 | 1 | 1 | 1 | 1 | 1 (4/5) | MA-CDT-VIBE | 1 | |
| 14 | 1 | 1 | 2 | 1 | 1 | 1 (5/5) | DL | 1 | |
| 14* | 1 | 1 | 1 | 1 | 1 | 1 (4/5) | DL | 1 | |
| 6 | 15 | 2 | 1 | 2 | 2 | 2 | 1 (5/5) | DL | 2 |
| 15* | 2 | 1 | 2 | 1 | 2 | 1 (5/5) | DL | 2 | |
| 16 | 2 | 1 | 1 | 1 | 1 | 1 (3/5) | MA-CDT-VIBE | 1 | |
| 16* | 1 | 1 | 1 | 1 | 1 | 1 (3/5) | DL | 1 | |
| 7 | 17 | 1 | 1 | 2 | 1 | 1 | 1 (4/5) | DL | 2 |
| 17* | 1 | 1 | 1 | 1 | 1 | 1 (4/5) | MA-CDT-VIBE | 1 | |
| 18 | 1 | 1 | 1 | 1 | 1 | 1 (4/5) | MA-CDT-VIBE | 1 | |
| 18* | 1 | 1 | 1 | 1 | 1 | 1 (5/5) | PV | 1 | |
| 8 | 19 | 2 | 2 | 1 | 1 | 1 | 1 (5/5) | MA-CDT-VIBE | 1 |
| 19* | 1 | 1 | 1 | 1 | 1 | 1 (5/5) | MA-CDT-VIBE | 1 | |
| 20 | 1 | 1 | 2 | 1 | 2 | 2 (--) | DL | 2 | |
| 20* | 1 | 1 | 2 | 1 | 2 | 1 (5/5) | DL | 2 | |
| 9 | 21 | 1 | 1 | 2 | 1 | 1 | 1 (4/5) | MA-CDT-VIBE | 1 |
| 21* | 1 | 1 | 1 | 1 | 1 | 1 (4/5) | MA-CDT-VIBE | 1 | |
| 10 | 22 | 1 | 1 | 2 | 1 | 1 | 1 (5/5) | MA-CDT-VIBE | 2 |
| 22* | 1 | 1 | 1 | 1 | 1 | 1 (5/5) | MA-CDT-VIBE | 1 | |
| 11 | 23 | 2 | 1 | 1 | 1 | 1 | 1 (5/5) | DL | 1 |
| 23* | 1 | 1 | 1 | 1 | 1 | 1 (5/5) | MA-CDT-VIBE | 1 | |
| 12 | 24 | 1 | 1 | 1 | 1 | 1 | 1 (3/5) | MA-CDT-VIBE | 1 |
| 24* | 1 | 1 | 1 | 1 | 1 | 1 (3/5) | MA-CDT-VIBE | 1 | |
| 13 | 25 | 1 | 1 | 2 | 1 | 1 | 1 (4/5) | MA-CDT-VIBE | 1 |
| 25* | 1 | 1 | 1 | 1 | 1 | 1 (4/5) | MA-CDT-VIBE | 1 | |
| 14 | 26 | 1 | 1 | 1 | 2 | 1 | 2 (5/5) | DL | 2 |
| 26* | 1 | 1 | 1 | 1 | 1 | 1 (5/5) | DL | 2 | |
| 15 | 27 | 2 | 1 | 2 | 1 | 1 | 1 (4/5) | MA-CDT-VIBE | 1 |
| 27* | 1 | 1 | 1 | 1 | 1 | 1 (4/5) | MA-CDT-VIBE | 1 | |
| 16 | 28 | 1 | 2 | 1 | 1 | 1 | 1 (4/5) | DL | 2 |
| 28* | 1 | 1 | 1 | 1 | 1 | 1 (4/5) | MA-CDT-VIBE | 1 | |
| 17 | 29 | 1 | 1 | 1 | 1 | 1 | 1 (5/5) | MA-CDT-VIBE | 1 |
| 29* | 1 | 1 | 1 | 1 | 1 | 1 (5/5) | MA-CDT-VIBE | 1 | |
| 18 | 30 | 2 | 1 | 2 | 2 | 1 | 1 (5/5) | MA-CDT-VIBE | 1 |
| 30* | 2 | 1 | 2 | 1 | 1 | 1 (5/5) | MA-CDT-VIBE | 1 | |
| 19 | 31 | 1 | 2 | 1 | 1 | 1 | 1 (5/5) | MA-CDT-VIBE | 1 |
| 31* | 1 | 1 | 1 | 1 | 1 | 1 (5/5) | MA-CDT-VIBE | 1 | |
| 20 | 32 | 1 | 1 | 1 | 1 | 1 | 1 (3/5) | PL | 2 |
| 32* | 1 | 1 | 1 | 1 | 1 | 1 (3/5) | PL | 2 | |
| 21 | 33 | 1 | 1 | 1 | 1 | 1 | 1 (3/5) | DL | 1 |
| 33* | 1 | 1 | 1 | 1 | 1 | 1 (3/5) | MA-CDT-VIBE | 1 | |
| κ p | 0.81 | 0.91 | 0.83 | 0.76 | 0.77 | 0.85 (0.74) | 0.68 | 0.87 | |
| In each sequence, 1 indicates yes, 2 indicates no; * iindicates the result of the second review. PV – portovenous phase; DL – late dynamic phase; ESAP – equivalent standard arterial phase. | |||||||||